Tarlatamab improves long term survival in previously treated small cell lung cancer

Share :
Published: 26 Oct 2026
Views: 1023
Rating:
Save
Prof Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

Prof Charles Rudin speaks to ecancer about the extended follow-up results from the phase III DeLLphi-304 trial, which evaluated tarlatamab, a DLL3-targeting bispecific T-cell engager immunotherapy, compared with chemotherapy in patients with small cell lung cancer (SCLC) whose disease had progressed after first-line platinum-based chemotherapy.

After a median follow-up of 23 months, tarlatamab continued to demonstrate a significant overall survival benefit, reducing the risk of death by 38%.

Median overall survival was 13.6 months with tarlatamab compared with 8.4 months with chemotherapy.

Dr Rudin says that the benefit was maintained in high-risk subgroups, including patients with platinum-resistant disease and those with brain metastases.

Tarlatamab also improved progression-free survival, with median progression-free survival of 4.2 months versus 3.2 months, and demonstrated more durable disease control.

Treatment discontinuations due to treatment-related adverse events were also lower with tarlatamab (3% vs 7%), and no new safety signals emerged with extended follow-up.

These findings reinforce the durable survival benefit and manageable safety profile of tarlatamab as a treatment option for patients with previously treated SCLC, including those with high-risk disease.

This information is intended for health care professionals only. The information is not intended for US health care professionals.

Related Videos

Tarlatamab's role in SCLC

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Tarlatamab's role in SCLC ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
15 Oct 2026

Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC

Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )
13 Oct 2026

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC ( Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA )
28 Sep 2026

Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC

Dr Chul Kim - Georgetown Cancer Institute, Washington, USA
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC ( Dr Chul Kim - Georgetown Cancer Institute, Washington, USA )
28 Sep 2026

JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )
18 Sep 2026

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
31 May 2026

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management? ( Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium )
11 May 2026

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )
23 Apr 2026

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer ( Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA )
15 Apr 2026